Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Opt-Out States and Physician-Led Anesthesia Care Explained
Anesthesiologists are warning that the so‑called “opt‑out” states do not eliminate the need for physician supervision of nurse anesthetists. While 25 governors have invoked the CMS opt‑out provision, most state statutes still mandate physician oversight. A 2024 California investigation found Doctors Medical Center in immediate jeopardy after allowing CRNAs to practice without physician orders, illustrating the regulatory risk. The article argues that patient safety, not political slogans, should drive anesthesia policy.
Study Surveys Dysfunctional Gene Splicing in Metastatic Kidney Disease
Researchers at City of Hope and its TGen division found that a tumor’s “splicing burden” – the frequency of aberrant gene‑splicing events – strongly correlates with clinical response in metastatic renal cell carcinoma (mRCC). By RNA‑sequencing 101 patient samples, they...
Study Links Childhood Adversity, Heart Disease Risk in Adulthood
A new UConn-led study published in *Ethnicity & Health* links adverse childhood experiences (ACEs) to a two‑fold increase in heart disease risk among Black Americans. Analyzing CDC Behavioral Risk Factor Surveillance System data from 2019‑2022, the researchers examined 30,746 respondents...
Bracco Launches BubbleGen™ Early Access Program for Microbubble-Based Cell Selection and Activation at ISCT
Bracco Imaging announced an Early Access Program for its new BubbleGen™ technology, which uses buoyant microbubbles to isolate and activate specific cell subtypes. The platform offers a one‑step, magnetic‑residue‑free alternative to traditional bead‑based cell separation, initially demonstrated with CD3⁺ T‑cell selection...
New Pharmaceutical Reform Alliance Poll: Americans Agree on One Thing – Rein in Big Pharma
The Pharmaceutical Reform Alliance released a new national poll of 1,524 registered voters showing overwhelming bipartisan support for prescription‑drug pricing reform. Eighty‑nine percent of respondents favor reform, while 68% say drug prices have risen and 94% blame pharmaceutical companies for...
NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324...
NImmune Biopharma presented Phase 1 data for its oral LANCL2 drug NIM‑1324 at Digestive Disease Week, showing safety, tolerability, target engagement and superior efficacy versus existing IBD therapies. The study met all primary and secondary endpoints with no dose‑limiting toxicities and...
Hepta Reveals Blood-Based Epigenetic Signatures of GLP-1 Response, Enabling Precision Medicine in Obesity and MASH
Hepta unveiled a blood‑based cfDNA methylation assay at Digestive Disease Week 2026 that can identify patients who will lose at least 10% of body weight on semaglutide before the first dose. The SAMARA trial showed baseline epigenetic signatures distinguished responders...
Conduction System Pacing Defibrillator Lead Successful in Trial
Abbott’s bipolar conduction‑system‑pacing (CSP) implantable cardioverter‑defibrillator lead met its primary safety and effectiveness endpoints in the pivotal ASCEND CSP trial presented at Heart Rhythm 2026. The study enrolled 205 patients needing left‑bundle‑branch‑area pacing, achieving a 98.5% implantation success rate and 97.5%...
Infigratinib
Infigratinib, a pan‑FGFR inhibitor previously approved for cholangiocarcinoma, is being repurposed to treat achondroplasia. After its FDA accelerated approval was rescinded in 2024 due to enrollment challenges, BridgeBio reported that the Phase 3 PROPEL 3 trial met its primary endpoint in February 2026....
Swiss Manufacturing, Biotech Industry so Far Unfazed by Geopolitics
Swiss pharmaceutical manufacturing remains stable despite looming US tariff threats and broader geopolitical tensions. Industry leaders say output levels and export volumes have held steady through 2023, while biotech firms continue robust R&D spending. Analysts note that some multinational drugmakers...
Patient-Facing Revenue Cycle Processes Improve Margins
Curae’s VP of operations, Matt Fisher, says that engaging patients at the first point of contact to address insurance coverage gaps can both improve care access and increase provider revenue. By deploying patient‑facing revenue cycle tools that verify eligibility and...
Patient-Facing Revenue Cycle Starts at the Front-End
Curae is launching a patient‑facing revenue cycle that begins at the front end of care, using artificial intelligence to pull together physician notes, clinical history, and claims data. Matt Fisher, VP of Operations, says the AI creates a single, comprehensive...
Haleon India Witnessing Double-Digit Growth Momentum, Open to Inorganic Growth Opportunities
Haleon India posted double‑digit growth in Q1, driven by a ₹20 (≈ $0.24) Sensodyne launch that attracted 70% new consumers. The company doubled its distribution footprint, with rural sales now accounting for a quarter of revenue. CEO Kedar Lele highlighted plans...
Rebecca Crews Talks About Getting New Parkinson’s Disease Treatment
Rebecca King Crews, a Parkinson’s disease patient and fashion entrepreneur, underwent MRI‑guided focused ultrasound thalamotomy in July 2025 and reported rapid symptom relief. The FDA expanded the device’s indication in July 2025 to allow staged bilateral treatments, which Crews completed...
HHS Unveils Plan To Curb Psychiatric Overprescribing, Encourage Tapering
The U.S. Department of Health and Human Services announced a coordinated plan to curb the overprescribing of psychiatric medications and promote safe tapering for patients. The initiative brings together the Administration for Children and Families, the Centers for Medicare &...
Why Are Medications Administered in Different Forms?
Medications are delivered via a spectrum of routes—from oral tablets to direct cardiac injections—chosen to align with the target organ, urgency of therapy, and patient-specific factors. While oral administration accounts for roughly 90% of treatments, gastrointestinal limitations or preservative sensitivities...
Connected by Design: How AI and Automation Are Transforming Drug Discovery at BMS
Bristol Myers Squibb (BMS) is shifting from isolated AI tools to an integrated, learning‑driven ecosystem that connects data, models, and automation across discovery and development. The company highlights its shared data backbone, AI co‑scientists, and lab‑in‑the‑loop automation as foundational layers,...
How I Learned To Trust AI as a Physical Therapist
Steven Griffin, a senior manager at TailorCare, describes his shift from skepticism to embracing AI in musculoskeletal (MSK) physical therapy. He explains that while MSK care’s nuanced, trust‑based nature resists full automation, AI tools—such as motion‑tracking, documentation scribes, and decision‑support...
Viridian Reports Positive Phase III REVEAL-2 Data for Elegrobart in Chronic Thyroid Eye Disease
Viridian Therapeutics announced that its subcutaneous IGF‑1R antibody elegrobart met the primary endpoint in the phase 3 REVEAL‑2 trial for chronic thyroid eye disease (TED). Patients receiving the drug every four or eight weeks showed 50‑54% proptosis responder rates and 55‑61%...
The Intelligence Gap: Why Oncologists Are Buried in Data While Patients Wait for Breakthroughs
Manan Sheth highlights a growing "intelligence gap" in oncology, where physicians juggle an average of 260 active patients while spending roughly 30% of their week on administrative tasks. Rapidly expanding clinical data outpaces human processing, contributing to a 20% failure...
What Physicians and Dragonflies Share in Resilience and Agility
The article draws a vivid parallel between physicians and dragonflies, highlighting shared traits of agility, rapid decision‑making, and resilience. Dragonflies’ four independent wings enable hovering, 30 mph flight, and even flight with a broken wing, while their 360° vision mirrors physicians’...
5 Key April FDA Approvals Signal Momentum Across Rare, Chronic Diseases
April 2026 saw five FDA approvals spanning HIV, type 1 diabetes, chronic spontaneous urticaria, genetic hearing loss, and systemic lupus erythematosus. Merck’s Idvysno introduced the first tenofovir‑free, non‑INSTI two‑drug HIV regimen, while Sanofi’s teplizumab received clearance for children as young as...
Emphasis on Cybersecurity in Medical Practices Could Protect Both Patients and Health Care
Healthcare providers are increasingly targeted by cyberattacks as digital workflows expand, raising the risk of data leaks and service disruptions. The February 2024 Change Healthcare ransomware incident exposed the records of roughly 192.7 million Americans and highlighted the vulnerability of even large...
The Medicaid Maternity Cliff: 84% of Health Plan Leaders Expect Major Care Disruption in 2026
Sage Growth Partners’ Q1 2026 report flags a looming "Medicaid Maternity Cliff," with 52% of Medicaid‑enrolled pregnant women expecting to lose coverage after eligibility redeterminations. The study finds 84% of health‑plan leaders anticipate moderate to severe disruption in maternal and infant...
Improving Social Support Among Sports Medicine Practitioners: A Call to Action
A new editorial in the British Journal of Sports Medicine highlights the growing mental‑health crisis among sports medicine practitioners, noting that roughly one‑third have sought psychological treatment. The authors cite research linking burnout to inadequate social support and argue that...
From Research to Practice: Barriers to Implementation of Psychologically Informed Practice in the Sports Setting
The British Journal of Sports Medicine article highlights psychologically informed practice (PiP) as a whole‑person approach that improves rehabilitation outcomes but remains underused in sports settings. While most evidence stems from non‑sport populations, the authors argue that system‑level barriers—such as...
Impact of Physical Activity Patterns on Major Adverse Cardiovascular Events in Adults with Hypertension
A UK Biobank analysis of 38,960 adults with hypertension followed for an average of 7.9 years found that both short (≤3 min) and long (>5 min) bouts of moderate‑intensity activity reduced the risk of major adverse cardiovascular events (MACE). Short bouts of...
Pressure Points: Ethical Dilemmas in Sports Mental Health Research Involving Athletes
The British Journal of Sports Medicine editorial highlights growing ethical dilemmas in mental‑health research involving elite athletes, where power imbalances, commercial pressures, and public scrutiny heighten risk. It argues that researchers must embed safeguards—such as clear referral pathways, confidentiality protocols,...
Edwards Names Theodora Mistras as CFO
Edwards Lifesciences announced Theodora “Doretta” Mistras will become its chief financial officer effective end of May, succeeding long‑time CFO Scott Ullem who will stay on as a strategic adviser. Mistras comes from a two‑year stint as CFO of Viatris and...
Kidney Care Is Value‑Based Care’s Toughest Economic Test — and It’s Working
Value‑based care has finally proven its worth in the most complex segment of U.S. healthcare—kidney care—through the Comprehensive Kidney Care Contracting (CKCC) program. Since its launch in 2022, CKCC participants have posted early shared savings, profitability, and measurable clinical improvements....
Key Biosimilars Events of April 2026
In April 2026 the biosimilar landscape saw a wave of regulatory approvals and strategic deals. The European Commission cleared Poherdy (pertuzumab) and Tuyory (tocilizumab), while Health Canada and China’s NMPA approved multiple denosumab biosimilars and granted IND clearances for Henlius’...
Two‑Week Elemental Diet Cuts IBS Symptoms by 30% in 82% of Patients
Researchers at Cedars‑Sinai presented data showing that a 2‑week exclusive elemental diet lowered abdominal pain, bloating and discomfort by 30% or more in 82% of IBS patients. The improvement persisted after participants returned to their regular diets, offering a concrete,...
Aspen Neuroscience Begins First Personalized Brain‑Repair Trial for Parkinson’s
Aspen Neuroscience announced the start of its ASPIRO Phase 1/2a trial, the first personalized brain‑repair therapy for Parkinson’s disease. Eight patients received autologous dopamine‑producing cells, reporting roughly two extra hours of “Good ON” time per day. The trial marks a...
Foundayo’s Liver Failure Blip Weighs Down Lilly Shares but Analysts Unconcerned
A single hepatic failure case linked to Eli Lilly’s new weight‑loss pill Foundayo appeared in the FDA’s adverse‑event database, prompting a brief sell‑off that pushed the stock down about 3% before rebounding to close up 0.48%. Lilly quickly investigated and...
CareFusion 213, LLC - 722729 - 04/30/2026
The FDA issued Warning Letter 320‑26‑72 to CareFusion 213, LLC, a BD subsidiary, citing extensive CGMP violations at its El Paso sterile drug facility. Inspectors documented over 2,500 customer complaints involving foreign particles, missing components, and compromised seals, and found the company’s investigations,...
Active Cosmetics Manufacturing Inc. - 722408 - 04/22/2026
The FDA issued a warning letter to Active Cosmetics Manufacturing Inc. after an October 2025 inspection uncovered multiple Current Good Manufacturing Practice (CGMP) violations. The firm failed to conduct thorough investigations of out‑of‑specification microbial results, used an inadequately validated rapid...
Intelligent Remedies, Inc. - 681941 - 01/23/2026
The FDA issued a warning letter (CMS #681941) to Intelligent Remedies, Inc., alleging that ten of its products—including Pryenda, Athrombosyn, and VIRAsol—are marketed with therapeutic claims that classify them as new drugs. The agency says the claims violate the Federal Food,...
Respilon Production S.R.O. - 719705 - 04/20/2026
The U.S. Food and Drug Administration issued Warning Letter 320‑26‑69 to Respilon Production S.R.O., a Czech over‑the‑counter drug manufacturer, citing multiple Current Good Manufacturing Practice (CGMP) violations. The FDA found failures in identity testing of components, lack of stability studies,...
Ray’s Vitamins - 726694 - 04/24/2026
The FDA issued a warning letter to Ray’s Vitamins after discovering that its product “Yeicob Ácido Hialurónico” contains undeclared diclofenac and dexamethasone, classifying it as an unapproved new drug and a misbranded drug. The agency cited violations of sections 301(d), 505(a) and...
Twist Bioscience Q2 2026 Loss Widens as Synthetic DNA Demand Slows
Twist Bioscience Corp posted a second‑quarter 2026 net loss of $44.0 million, or $0.71 per share, compared with a $39.3 million loss a year ago. Revenue rose 19.3% to $110.7 million, but the widening loss highlights pressure on the synthetic‑DNA market as demand...
Buyers Spending Less on Fewer Items in Vision Care Market
U.S. consumers cut overall spending on vision‑care products in Q1 2026, opting for lower‑priced eyeglasses and smaller contact‑lens supplies. The Vision Council reports a shift toward budget frames under $100 and a majority (53%) purchasing three‑month or shorter lens supplies....
Sun Pharma to Acquire Organon for $12 Billion, Its Largest U.S. Deal Yet
Sun Pharmaceutical Industries Ltd. announced a $12 billion all‑cash acquisition of New Jersey‑based Organon & Co., the biggest U.S. outbound deal for an Indian drugmaker this year. The transaction pushes Sun Pharma into the specialty‑medicine arena and tests its ability to...
Multivitamins Show No Overall BP Benefit, Help Low‑Diet Individuals
Long-Term Effect of Multivitamin Supplementation on Incident Self-Reported Hypertension and Blood Pressure Changes in the COSMOS Trial "MVM supplementation versus placebo did not reduce hypertension incidence or lower BP overall. Exploratory analyses showed greater reduction in hypertension risk and BP changes...
Payers May Price Risk Pools by City or ZIP
“High-risk cities” could see double-digit PMPM growth above national averages. This means that Payers may begin pricing city-level or even ZIP-level risk pools. https://t.co/B9YFDKiXoX
Insulet Launches Pivotal Trial of Fully Closed‑Loop Insulin System for Type 2 Diabetes
Insulet Corp. has begun a pivotal clinical trial, called Evolve, enrolling up to 350 adults with Type 2 diabetes across 40 U.S. sites. The study tests the company’s first fully closed‑loop insulin delivery system, a move intended to broaden automated insulin...
MRI Body Composition Predicts Diabetes, Heart Events, Mortality
Body composition from MRI of 66,000 people was linked to diabetes, major cardiovascular events, and all-cause mortality @radiology_rsna https://t.co/KUkMppvorA https://t.co/FdyHjpWqW1
Cytospire Secures $83M to Develop Novel T‑Cell Engager
Cytospire hauls in $83M for a new type of T cell engager https://t.co/19BkL5JiHk by @gwendolynawu #biotech #startups
HealthStream Posts 1% Q1 2025 Revenue Rise, Leans on SaaS Growth Amid Legacy Decline
HealthStream (HSTM) posted Q1 2025 revenue of $73.5 million, a 1% rise year‑over‑year, thanks to strong SaaS bookings and a $14 million five‑year contract. Legacy credentialing and scheduling losses and a customer bankruptcy weighed on operating income, which fell 23% to $4.4 million.
Quantum Breakthrough: 10-Year Partnership Yields Discovery Accelerator
Next up - Quantum with @ClevelandClinic's Serpil Erzurum - talking about the discovery accelerator - result of a 10 year partnership. #IBMThink https://t.co/LwGwuFTvgf
US Exit From WHO Risks Missing Outbreak Alerts
As an outbreak, #hantavirus on a cruise ship is more interesting than alarming. But it should serve as a warning sign to the US, which by withdrawing from #WHO has cut itself off from WHO's outbreak intelligence network, writes @KrutikaKuppalli. https://t.co/WdEaLOWf1f